4. When implementing acute blood pressure lowering after mild to moderate ICH, treatment regimens that limit blood pressure variability and achieve smooth, sustained blood pressure control appear to ...

Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis Kiniksa is on track to initiate a Phase 2/3 clinical trial designed to evaluate the efficacy and safety of KPL-387 administered ...

Kiniksa is on track to initiate a Phase 2/3 clinical trial designed to evaluate the efficacy and safety of KPL-387 administered subcutaneously (SC) in patients with recurrent pericarditis. The trial ...

Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis Kiniksa is on track to initiate a Phase 2/3 clinical trial designed to evaluate the efficacy and safety of KPL-387 administered ...

In regard to treatment preferences among patients with acute episodic migraine, most patients prioritized pain relief and avoiding adverse outcomes over other treatment attributes such as cost and ...

CERO Therapeutics announces first patient dosed in Phase 1 trial of CER-1236 for acute myeloid leukemia, with upcoming ASCO presentation. CERo Therapeutics Holdings, Inc. has announced the initial ...

His appointment comes at an important time in Cardiol's growth as we advance our pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis and prepare for database lock ...

recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest ...

ABSTRACT: Staphylococcus aureus pericarditis is a rare but life-threatening condition that often presents as purulent pericarditis and in rare cases can lead to constrictive pathophysiology.

ABSTRACT: Staphylococcus aureus pericarditis is a rare but life-threatening condition that often presents as purulent pericarditis and in rare cases can lead to constrictive pathophysiology.